

A Novel Clinical Entity: Triglyceride Deposit Cardiomyopathy Perspectives from "Obesity of the Heart"

Journal of Atherosclerosis and Thrombosis

16, 702-705

DOI: 10.5551/jat.1669

Citation Report

#	ARTICLE	IF	CITATIONS
1	Role of Lipotoxicity in Endothelial Dysfunction. Heart Failure Clinics, 2012, 8, 589-607.	2.1	94
2	Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nature Chemical Biology, 2013, 9, 785-787.	8.0	163
3	Quantitative proteomic analysis of cultured skin fibroblast cells derived from patients with triglyceride deposit cardiomyovasculopathy. Orphanet Journal of Rare Diseases, 2013, 8, 197.	2.7	11
4	Vascular smooth muscle cells isolated from adipose triglyceride lipase-deficient mice exhibit distinct phenotype and phenotypic plasticity. Biochemical and Biophysical Research Communications, 2013, 434, 534-540.	2.1	12
5	A Peptide Derived from G0/G1 Switch Gene 2 Acts as Noncompetitive Inhibitor of Adipose Triglyceride Lipase. Journal of Biological Chemistry, 2014, 289, 32559-32570.	3.4	39
6	Impact of diabetes mellitus on myocardial lipid deposition: An autopsy study. Pathology Research and Practice, 2014, 210, 1018-1025.	2.3	18
7	Coronary triglyceride deposition in contemporary advanced diabetics. Pathology International, 2014, 64, 325-335.	1.3	26
8	Genetic mutations in adipose triglyceride lipase and myocardial up-regulation of peroxisome proliferated activated receptor- α 3 in patients with triglyceride deposit cardiomyovasculopathy. Biochemical and Biophysical Research Communications, 2014, 443, 574-579.	2.1	41
9	Peripheral leukocyte anomaly detected with routine automated hematology analyzer sensitive to adipose triglyceride lipase deficiency manifesting neutral lipid storage disease with myopathy/triglyceride deposit cardiomyovasculopathy. Molecular Genetics and Metabolism Reports, 2014, 1, 249-253.	1.1	6
10	Novel missense mutations in PNPLA2 causing late onset and clinical heterogeneity of neutral lipid storage disease with myopathy in three siblings. Molecular Genetics and Metabolism, 2015, 115, 110-117.	1.1	35
11	Change in Plasma Total, Esterified and Non-esterified Capric Acid Concentrations during a Short-term Oral Administration of Synthetic Tricaprin in Dogs. Analytical Sciences, 2017, 33, 1297-1303.	1.6	9
12	Imaging Modalities for Triglyceride Deposit Cardiomyovasculopathy. Annals of Nuclear Cardiology, 2017, 3, 94-102.	0.2	15
13	Newly developed selective immunoinactivation assay revealed reduction in adipose triglyceride lipase activity in peripheral leucocytes from patients with idiopathic triglyceride deposit cardiomyovasculopathy. Biochemical and Biophysical Research Communications, 2018, 495, 646-651.	2.1	10
14	Diagnostic Criteria and Severity Score for Triglyceride Deposit Cardiomyovasculopathy. Annals of Nuclear Cardiology, 2018, 4, 94-100.	0.2	11
15	Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder. Orphanet Journal of Rare Diseases, 2019, 14, 134.	2.7	34
16	Prevalence and clinical outcomes of triglyceride deposit cardiomyovasculopathy among haemodialysis patients. Heart, 2021, 107, 127-134.	2.9	12
17	Electron Microscopy Revealed Massive Lipid Droplets in Cardiomyocytes in a Patient with Cardiogenic Shock Following a Fulminant Type 1 Diabetes Mellitus. International Heart Journal, 2021, 62, 197-200.	1.0	5
18	Triglyceride Deposit Cardiomyovasculopathy with Massive Myocardial Triglyceride which Was Proven Using Proton-magnetic Resonance Spectroscopy. Internal Medicine, 2021, 60, 1217-1220.	0.7	1

#	ARTICLE	IF	CITATIONS
19	The Diagnostic Criteria 2020 for Triglyceride Deposit Cardiomyovasculopathy. <i>Annals of Nuclear Cardiology</i> , 2020, 6, 99-104.	0.2	16
20	Triglyceride Deposit Cardiomyovasculopathy, TGCV-To Overcome This Intractable Disease One Day Sooner-. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 2385-2390.	0.0	3
21	Triglyceride Deposit Cardiomyovasculopathy. , 2019, , 111-119.		1
22	Correlation Perspectives for the Diagnosis of Idiopathic Triglyceride Deposit Cardiomyovasculopathy. <i>Annals of Nuclear Cardiology</i> , 2020, 6, 33-38.	0.2	6
23	Triglyceride deposit cardiomyovasculopathy: how to recognise a new disease entity. <i>Heart</i> , 2021, 107, 93-95.	2.9	7
24	Clinical significance of 123I-BMIPP washout rate in patients with uncertain chronic heart failure. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3129-3139.	6.4	6
25	Outside-in signaling by femoral cuff injury induces a distinct vascular lesion in adipose triglyceride lipase knockout mice. <i>Histology and Histopathology</i> , 2021, 36, 91-100.	0.7	0
26	^{123I}-BMIPP Scintigraphy Shows That CNT-01 (Tricaprin) Improves Myocardial Lipolysis in Patients with Idiopathic Triglyceride Deposit Cardiomyovasculopathy. <i>Annals of Nuclear Cardiology</i> , 2022, 8, 67-75.	0.2	7
27	Methods of calculating 123I- ¹²³ I- ¹²³ I- ¹²³ I-methyl-P-iodophenyl-pentadecanoic acid washout rates in triglyceride deposit cardiomyovasculopathy. <i>Annals of Nuclear Medicine</i> , 2022, 36, 986-997.	2.2	5
28	Medium-chain triglycerides (8:0 and 10:0) increase muscle mass and function in frail older adults: a combined data analysis of clinical trials. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	0